Improved overall survival in head and neck cancer patients after specific therapy of distant metastases
- 71 Downloads
While metastases directed therapy for oligometastatic disease is recommended in different cancer entities, the treatment of solitary metastases in head and neck squamous cell carcinoma (HNSCC) patients is not clearly defined.
A retrospective analysis was performed on data from 143 HNSCC patients treated between 2001 and 2016 in a tertiary university hospital. Clinical factors and outcome were measured using the median survival of patients receiving metastases specific therapy in comparison with matched control patients.
In 37 patients, distant metastases were treated specifically with either surgery and/or stereotactic ablative radiotherapy and had with 23.97 months a more than three times higher median survival than 10 untreated matched controls with potentially treatable distant metastases (7.07 months).
Our retrospective analysis demonstrates a significant survival benefit for HNSCC patients who received a specific therapy regarding distant metastasis irrespective of localization as compared to a matched control cohort.
KeywordsHNSCC Distant metastases Specific treatment Overall survival Radiotherapy
The authors gratefully acknowledge Armin Ott from the Institute for Medical Statistics and Epidemiology at Technical University of Munich for his advice on the statistical analysis.
Compliance with ethical standards
Conflict of interest
All authors have no conflicts of interest.
Only routine clinical data were retrospectively collected from patients’ charts and pseudonymously analyzed, and therefore, no formal ethical approval was obtained. We declare that all authors have contributed to read and approved the final manuscript for submission.
- 5.National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology head and neck cancers (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 23 Sept 2016
- 14.Mehanna H et al (2010) Head and neck cancer—Part 2: treatment and prognostic factors. BMJ 341(c4690):721–725Google Scholar